{"id":"NCT02694536","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer","officialTitle":"A Phase IIIb Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08-01","primaryCompletion":"2009-11-19","completion":"2009-11-19","firstPosted":"2016-02-29","resultsPosted":"2017-01-10","lastUpdate":"2017-03-24"},"enrollment":80,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pancreatic Cancer"],"interventions":[{"type":"DRUG","name":"Erlotinib","otherNames":["Tarceva"]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]}],"arms":[{"label":"Erlotinib + Gemcitabine","type":"EXPERIMENTAL"}],"summary":"This open-label, single-arm, multicenter trial is designed to evaluate the safety of erlotinib in combination with standard of care chemotherapy (gemcitabine) in participants with locally advanced, unresectable, or metastatic pancreatic cancer.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs)","timeFrame":"Up to approximately 40 months (assessed continuously during treatment)","effectByArm":[{"arm":"Erlotinib + Gemcitabine","deltaMin":78.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":11,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":80},"commonTop":["Anaemia","Thrombocytopenia","Leukopenia","Pyrexia","Neutropenia"]}}